Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Gamco Investors INC. ET AL

Gamco Investors INC. ET AL boosted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 54.2% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 563 shares of the biopharmaceutical company’s stock after buying an additional 198 shares during the quarter. Gamco Investors INC. ET AL’s holdings in Regeneron Pharmaceuticals were worth $401,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Pamalican Asset Management Ltd acquired a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at $4,915,000. Intact Investment Management Inc. acquired a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth about $356,000. Rhenman & Partners Asset Management AB lifted its stake in Regeneron Pharmaceuticals by 11.4% in the 4th quarter. Rhenman & Partners Asset Management AB now owns 43,457 shares of the biopharmaceutical company’s stock valued at $30,956,000 after buying an additional 4,457 shares in the last quarter. Principal Financial Group Inc. increased its stake in Regeneron Pharmaceuticals by 1.7% during the 3rd quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company’s stock worth $181,961,000 after buying an additional 2,828 shares in the last quarter. Finally, Fagan Associates Inc. lifted its position in shares of Regeneron Pharmaceuticals by 42.2% in the fourth quarter. Fagan Associates Inc. now owns 12,923 shares of the biopharmaceutical company’s stock valued at $9,205,000 after acquiring an additional 3,832 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock opened at $563.16 on Friday. Regeneron Pharmaceuticals, Inc. has a one year low of $525.99 and a one year high of $1,211.20. The business has a 50-day simple moving average of $645.94 and a 200-day simple moving average of $738.44. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The company has a market cap of $61.57 billion, a PE ratio of 14.71, a P/E/G ratio of 2.34 and a beta of 0.44.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $11.21 by $0.86. The business had revenue of $3.79 billion during the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same period in the previous year, the company earned $11.86 EPS. On average, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.63%. The ex-dividend date was Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 2.30%.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. Robert W. Baird reduced their price objective on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating for the company in a research note on Wednesday, February 5th. The Goldman Sachs Group dropped their price objective on shares of Regeneron Pharmaceuticals from $1,019.00 to $917.00 and set a “buy” rating for the company in a research note on Monday, April 14th. Sanford C. Bernstein lowered their target price on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a report on Tuesday, January 7th. Wells Fargo & Company reduced their price objective on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a research report on Friday, January 10th. Finally, Bernstein Bank reduced their price target on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a report on Tuesday, February 4th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, eighteen have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $963.56.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.